Recent research have converged on the convergence of GLP-1|glucose-dependent insulinotropic polypeptide|glucagon receptor agonist therapies and dopaminergic neurotransmission. While GCGR activators are increasingly employed for treating type 2 T2DM, their unexpected consequences on reinforcement